Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11089929 | 0.86 | EIF2AK2 (0.63) | EIF2AK2MAOBAHRGRIA1CACNG8 | |
| SCHEMBL11089100 | 0.84 | AHR (0.68) | EIF2AK2MAOBAHRGRIA1CACNG8 | |
| SCHEMBL3484612 | 0.82 | MAOB (0.50) | EIF2AK2MAOBAHRCRBNGRIA1 | |
| SCHEMBL22660 | 0.81 | AHR (0.61) | EIF2AK2AHRGRIA1CACNG8PDE3B | |
| SCHEMBL10711906 | 0.80 | PDE3B (0.68) | AHRCRBNGRIA1CACNG8PDE3B | |
| Bromide SCHEMBL9824774 | 0.80 | AHR (0.59) | EIF2AK2AHRGRIA1CACNG8PDE3B | |
| Hydrochloric Acid SCHEMBL15206761 | 0.80 | AHR (0.59) | EIF2AK2AHRGRIA1CACNG8PDE3B | |
| SCHEMBL28118843 | 0.79 | MAOB (0.65) | EIF2AK2MAOBAHRCRBN | |
| SCHEMBL20214 | 0.77 | PDE3B (0.66) | EIF2AK2MAOBAHRGRIA1CACNG8 | |
| SCHEMBL31040124 | 0.77 | PDE3B (0.66) | EIF2AK2MAOBAHRGRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | claimed |
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| EP-1370527-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| WO-2002070478-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | claimed |
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370527-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002070478-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | HYOU1, IDO1, OXER1 | EIF2AK2 3031/4885MAOB 581/4885AHR 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.